Second child cleared of leukaemia after Cellectis T-cell treatment
May 10, 2016Manufacturing and Production, Research and Development cellecits, childhood, children, designer cells, leukaemia, rare, t cells, t-cells
A targeted T-cell oncology therapy has successfully treated a second baby with aggressive leukaemia who has remained in remission after …
China evaluating investigations into pharma firms to take on drug pricing issue
May 9, 2016Business Services, Research and Development, Sales and Marketing China, France, G7, regulation
Lawmakers globally have acknowledged the concerns over unbridled drug costs as regulators stress the need for a more open debate …
UK pharma would benefit by remaining in EU, says ABPI
May 9, 2016Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing ABPI, Andrew Witty, EU, brexit, letter, observer, pascal soriot, remain, stay
With the EU vote approaching, the Association of the British Pharmaceutical Industry (ABPI) has brought together 93 signatories, including the …
Focus: Governments evaluate policies, reforms as drug pricing debate rages on
May 9, 2016Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing
By Anjali Shukla Lawmakers in France are set to urge the leaders of G7 countries to put in place guidelines …
Chiesi set to acquire Medicine Co cardiovascular assets, say reports
May 9, 2016Sales and Marketing Chiesi, assets, cardiovascular, medicine co
Italian pharmaceutical company Chiesi are set to expand their global footprint as it nears an agreement to acquire Medicines Co’s …
Endo shares plunge almost 40% as company cuts FY outlook
May 9, 2016Sales and Marketing Endo International, earnings, outlook, revenue
Shares in Endo International (Nasdaq: ENDP) plunged to close down nearly 40% after the company cut its full-year earnings forecast …
BTG acquires promising oncology pipeline in Galil Medical takeover
May 9, 2016Manufacturing and Production, Research and Development, Sales and Marketing $84 million, BTG, cryoablation, galil medical, oncology, takeover
BTG (LSE: BTG) has announced that is has agreed to acquire Galil Medical, a leading provider of cryoablation products for …
Phase III trial meets primary endpoint for Allergan’s fibroid treatment
May 9, 2016Manufacturing and Production, Research and Development, Sales and Marketing Allergan, fibroid, phase 3, phase III, ulipristal, ulipristal acetate, uterine fibroid
Allergan (NYSE: AGN), in collaboration with Gedeon Richter, has announced positive results from a pivotal Phase III trial evaluating the …
Weekly Movers: Bind Therapeutics, Sarepta, Idexx…
May 9, 2016Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing
Pfizer (NYSE: PFE) and Amgen (Nasdaq: AMGN) are rumoured to be considering a bid for Medivation just as French drug …
Clovis cuts staff by 35% after FDA knock back on lung cancer drug
May 6, 2016Manufacturing and Production, Research and Development, Sales and Marketing FDA, Q1 results, clovis, failure, job cuts, job losses, rociletinib, workforce
Clovis Oncology (NASDAQ: CLVS) is set to cut up to 35% of its workforce following the US Food and Drug …
NICE recommends Sanofi, Amgen cholesterol drugs
May 6, 2016Medical Communications, Sales and Marketing Amgen, Draft Guidance, NHS, NICE, Repatha, Sanofi, cardiovascular disease, cholesterol, final draft guidance, high cholesterol, praluent, recommendation, treatment
The National Institute for Health and Care Excellence (NICE) has issued final draft guidance recommending two new drugs for the …
KemPharm’s pain drug fails to get FDA committee backing for abuse-deterrent capabilities; shares plunge
May 6, 2016Medical Communications, Sales and Marketing
Shares in KemPharm (Nasdaq: KMPH) more than halved in pre-market trading after a US Food and Drug Administration advisory panel …
Focus: Medivation tug-of-war rumbles on
May 6, 2016Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Amgen, AstraZeneca, Medivation, Pfizer, Sanofi, billion dollar, competition, oncology, pipeline, promising, takeover, tug of war
Medivation (NASDAQ: MDVN) has been making all the headlines as a list of suitors’ line up, all vying to secure …
Merck & Co Q1 sales hurt by generics, currency impact
May 6, 2016Medical Communications, Sales and Marketing Financial, Merck & Co, Q1, Revenye, earnings, results, sales
US pharma major Merck & Co (NYSE: MRK) posted a drop in first-quarter sales impacted the launch of generic competition …
Valeant announces new patient access and pricing committee; vows to correct past “mistakes”
May 6, 2016Medical Communications, Sales and Marketing Valeant, joseph papa, new committee, patient access, price gouging, pricing
Valeant (NYSE: VRX) has announced the establishment of a new patient access and pricing committee that will be responsible for …
Pfizer teams up with Wave Life Sciences for metabolic disease research
May 6, 2016Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Pfizer, metabolic disease, nucelic acid therapies, partnership, wave life sciences
Pfizer (NYSE: PFE) has entered into a research, license and option agreement with Wave Life Sciences (NASDAQ: WVE) for the …
Amgen looking to join the fray, mulling Medivation bid – Reports
May 5, 2016Research and Development, Sales and Marketing Amgen, AstraZeneca, Deals, M&A, MA, Medivation, Pfizer, Sanofi
Biotech firm Amgen (Nasdaq: AMGN) is mulling a bid for Medivation (Nasdaq: MDVN), the latest to join the growing list …
Valeant’s Bausch + Lomb teams up with IBM for cataract surgery app
May 5, 2016Research and Development Bausch and Lomb, Valeant, app, cataract, cataract surgery, ibm, ipad, iphone, surgeons
IBM (NYSE: IBM) and Bausch + Lomb, a wholly owned subsidiary of Valeant (NYSE: VRX), have announced a partnership that …
Sanofi sends letter to Medivation board; claims shareholders want takeover
May 5, 2016Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing CEO, Medivation, Sanofi, board, brandicourt, hostile, shareholders, takeover
The CEO of Sanofi has issued a strongly worded letter to the board at Medivation, indicating that shareholders support their …
Eisai says European Commission backs Halaven to treat of advanced Liposarcoma in Europe
May 5, 2016Research and Development, Sales and Marketing EC, Eisai, US FDA, oncology, regulation, soft tissue sarcoma
The European Commission has backed marketing for the Japanese drug major Eisai’s (TYO: 4523) Halaven (eribulin) to treat advanced soft …
Latest content
NIHR chief scientific adviser visits Huddersfield health innovation campus
One in three UK women with migraine say symptoms taken less seriously
Report highlights scope to expand day surgery
Sygnature formalises drug discovery collaboration with X-Chem
Codis appoints Steven Facer as chief commercial officer
